$ARGX News

Wedbush Maintains Outperform on argenx, Raises Price Target to $1050

Forte: 'Hold' On Positive FB102 Vitiligo Treatment Data And argenx Acquisition For $2.2 Billion

Baird Maintains Neutral on argenx, Raises Price Target to $932

Oppenheimer Maintains Outperform on argenx, Raises Price Target to $1037

RBC Capital Maintains Outperform on argenx, Raises Price Target to $1025

Guggenheim Maintains Buy on argenx, Raises Price Target to $1185

argenx: Vyvgart Is Taking Off (Rating Upgrade)

Citizens Maintains Market Outperform on argenx, Lowers Price Target to $932

argenx Q2 2026 Earnings Call: Complete Transcript

argenx Q2 EPS $7.32 Beats $6.24 Estimate, Sales $1.542B Beat $1.442B Estimate

Citigroup Maintains Buy on argenx, Raises Price Target to $1182

RBC Capital Maintains Outperform on argenx, Raises Price Target to $945

B of A Securities Maintains Buy on argenx, Raises Price Target to $1088

HC Wainwright & Co. Reiterates Buy on argenx, Maintains $940 Price Target

Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1180

If You Invested $100 In argenx Stock 5 Years Ago, You Would Have This Much Today

Wedbush Reiterates Outperform on argenx, Maintains $1000 Price Target

Wedbush Reiterates Outperform on argenx, Maintains $1000 Price Target

argenx to Share New VYVGART Data for Autoimmune Diseases at EULAR

Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1291